Mirati Therapeutics Inc.
(NASDAQ : MRTX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
0.63%105.161.1%$1250.41m
GILDGilead Sciences, Inc.
0.43%72.820.9%$635.59m
AMGNAmgen Inc.
0.07%169.961.1%$483.52m
BIIBBiogen Inc.
0.24%309.801.2%$426.39m
REGNRegeneron Pharmaceuticals, Inc.
0.81%387.542.7%$354.48m
ALXNAlexion Pharmaceuticals, Inc.
-0.42%107.601.9%$279.93m
VRTXVertex Pharmaceuticals Incorporated
1.33%147.041.9%$234.21m
ALNYAlnylam Pharmaceuticals, Inc
0.24%132.3310.0%$190.13m
INCYIncyte Corporation
0.05%99.002.5%$178.71m
NKTRNektar Therapeutics
-0.46%49.756.1%$170.43m
ILMNIllumina, Inc.
1.56%215.353.5%$165.34m
JUNOJuno Therapeutics, Inc.
2.65%60.3313.5%$136.10m
AAgilent Technologies, Inc.
-1.75%68.691.5%$131.83m
SRPTSarepta Therapeutics, Inc.
0.66%56.2216.8%$117.39m
BLUEBluebird Bio, Inc.
-0.03%167.2017.2%$114.30m

Company Profile

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of oncology products to treat genetic and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.